- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT04068909
ObseRvation After Acute Coronary Syndrome for deveLopment of trEatment Options (ORACLE)
Exacerbation of Coronary Heart Disease: the Logic and Probabilistic Processes of Flow Prediction for Optimization of Treatment
The aim of the study is developing an individualized risk model for the unfavorable outcomes of coronary artery disease and complications from ongoing therapy, according to clinical, instrumental, biochemical and genetic parameters in patients with acute coronary syndrome.
Inclusion criteria: patients with acute coronary syndrome (with or without ST elevation) who have indications for PCI Number of inclusion patients - 1655 patients Scheduled time of follow up - 24 month Primary end-point: all-cause death Secondary end-points: any cardiovascular events (cardiovascular death, nonfatal myocardial infarction, non-fatal stroke); non-fatal myocardial infarction; recurrent acute coronary syndrome; non-fatal stoke; complicated atherosclerosis; recurrent PCI; bleeding
연구 개요
상태
정황
상세 설명
The role of genetic factors in the development of coranary heart disease (CHD) exacerbations studied not enough. Most research in this area planned and carried out on a "case-control". Using a similar protocol entails significant errors are associated with a high incidence of subclinical atherosclerotic vascular lesions. Moreover, much of atheroma is extravasal, making it impossible to identify them by angiography. Therefore, necessary to conduct prospective studies to estimate the frequency of so-called hard endpoints. Previously, similar trials were conducted, mainly in connect with drug approving procedures. The spread data from them to other patients directly is not entirely justified. At the same time, the influence of genetic factors in this group of patients can be substantial.
In the previous part of the study, the sample of patients of Moscow, St. Petersburg, Kazan, Chelyabinsk, Stavropol, Perm, and Rostov-on-the-Don was formed, of 1,200 people admitted due to acute coronary syndrome (ACS) including unstable angina and acute myocardial infarction, at coronary care units with follow-up for three years. We found several factors, including genetic, that significantly affect the outcomes of the disease. Coronary atherosclerosis and its complications now considered as a multifactorial disease associated with inherent factors. Therefore, the project provides, besides accounting a significant amount of clinical and instrumental data, the determination of a wide range of genotypes and alleles of polymorphic markers candidate genes encoding the protein factors of the hemostatic system, enzymes of lipid metabolism system, and anti-inflammatory cytokines. It is assumed that the prediction outcomes of coronary heart disease should be carried out taking into account the fact that several factors (gender, diabetes, age, aortic stenosis, atrial fibrillation, etc.) can not only significantly change the forecast itself but also affecting the significance of other risk factors. Since the last study, the standards significantly of ACS management changed. Invasive treatment not only creates opportunities to reduce coronary mortality but also increased demands on the patient's adherence to the assigned medication and creates additional risks associated with its activity (especially with an antithrombotic treatment activity). In these circumstances, the development of personalized approaches to prescribing drugs is particularly important. Thus, the prediction of coronary heart disease outcomes after an ACS on a set of clinical, instrumental, biochemical and genetic indicators is of great importance, as it allows to plan the most optimal treatment for the individual patient.
The aim of the study was to develop a model of individualized risk of coronary heart disease outcomes and side effects of therapy based on clinical and instrumental, biochemical, and genetic parameters in patients with ACS.
연구 유형
등록 (실제)
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
설명
Inclusion Criteria:
Patients with acute coronary syndrome without ST-segment elevation meeting the criteria of a very high, high or intermediate risk, and patients from the low-risk group, if they have episodes of myocardial ischemia in any way Very high risk (1 criterion is sufficient)
- Pulmonary edema, most probably due to ischemia.
- The newly appears or increased noise of mitral regurgitation.
- Rhythm of the gallop, newly developed or intensified wheezing in the lungs.
- Hypotension against ischemia
- Ischemia refractory to treatment
Persistent ventricular tachycardia or the occurrence of ventricular rhythm disturbances during an attack of ischemia High risk
(1 criterion is sufficient)
- An anginal attack more than 20 minutes within the next 48 hours before admission
- Transitional elevations ST (duration less than 20 min)
- GRACE score > 140 points
- Increased cardiospecific markers of necrosis. (you must have at least 2 criteria)
- Age> 75 years.
- Angina pectoris with transient changes ST> 0.05 mV.
Intermediate risk (1 criterion is sufficient)
- Age> 75 years.
- Angina pectoris with transient changes ST> 0.05 mV.
- Inversion of the T wave on ECG (≥ 0.2 mV).
- GRACE score 104-139 points
(it is necessary to have at least 2 criteria)
- Angina of rest (<20 min), stopped spontaneously or with the help of nitroglycerin (NG).
- Anamnesis of pathology of peripheral or cerebral arteries,
- Postponed myocardial infarction, including painless, history of revascularization (PCI or CABG)
- Diabetes.
- Chronic renal failure (GFR <50 mL / min)
Low risk All other patients with suspicion of ACS require a survey to identify episodes of ischemia
Patients with acute coronary syndrome with ST-segment elevation
Patients who were hospitalized with symptoms due to acute myocardial infarction (the duration of infarction is no more than 10 days, by the time of hospitalization) and at least one of the following additional criteria identified upon admission to hospital:
- ST elevation: a persistent ST increase of 1 mm in two adjacent leads from the limbs, or an ST increase of 2 mm in two adjacent thoracic leads
- the appearance of a new left bundle branch block
- dynamics of acute myocardial infarction
- Signed informed consent to participate in the study
Exclusion Criteria:
- Lack of patient consent to participate in the study
- Impossibility of contact with the patient after discharge after index event
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 관찰 모델: 보병대
- 시간 관점: 유망한
코호트 및 개입
그룹/코호트 |
---|
acute coronary syndrome
All patients should receive standard therapy for acute coronary syndrome and concomitant diseases.
All drugs are prescribed according current guidelines and approved indications.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
all-cause death
기간: Number of Participants with end-point during 360 days
|
death from any cause
|
Number of Participants with end-point during 360 days
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
cardiovascular events
기간: Number of Participants with end-point during 360 days
|
cardiovascular death, non-fatal myocardial infarction, non-fatal stroke
|
Number of Participants with end-point during 360 days
|
non-fatal myocardial infarction
기간: Number of Participants with end-point during 360 days
|
non-fatal myocardial infarction
|
Number of Participants with end-point during 360 days
|
recurrent acute coronary syndrome
기간: Number of Participants with end-point during 360 days
|
all cases of recurrent myocardial infarction or unstable angina after the index events
|
Number of Participants with end-point during 360 days
|
recurrent PCI
기간: Number of Participants with end-point during 360 days
|
all cases of recurrent PCI after the index hospitalization
|
Number of Participants with end-point during 360 days
|
complicated atherosclerosis
기간: Number of Participants with end-point during 360 days
|
peripheral atherosclerosis need hospitalisation
|
Number of Participants with end-point during 360 days
|
non-fatal stroke
기간: Number of Participants with end-point during 360 days
|
all cases of non-fatal stroke
|
Number of Participants with end-point during 360 days
|
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
bleeding
기간: Number of Participants with end-point during 360 days
|
all cases of bleeding during and after the index hospitalization
|
Number of Participants with end-point during 360 days
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Dmitry A Zateyshchikov, prof, Central State Medical Academy
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (예상)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
급성관상동맥증후군에 대한 임상 시험
-
Chinese Academy of Medical Sciences, Fuwai HospitalMedtronic; CCRF Consulting Co., Ltd.빼는Transradial-transfemoral Coronary Interventions 비교
-
CCRF Consulting Co., Ltd.Peking University First Hospital; Terumo Medical(shanghai) Co.,Ltd.알려지지 않은심장 또는 뇌혈관 질환 무료 요금 | Transradial-transfemoral Coronary Interventions 비교중국
-
Hospital Clinic of BarcelonaAstraZeneca완전한CTO(Chronic Total Occlusion)를 위한 PCI(Percutaneous Coronary Intervention)를 받을 예정인 환자스페인
-
Icahn School of Medicine at Mount SinaiNational Institute on Deafness and Other Communication Disorders (NIDCD)완전한
-
Basaksehir Cam & Sakura Şehir Hospital완전한
-
China Medical University Hospital알려지지 않은
-
Wolfson Medical Center빼는Ovarian Hyperstimulation Syndrome(OHSS)의 위험 감소를 위한 Coasting에 대한 GnRH 길항제의 증량 투여
-
Jazz Pharmaceuticals모병결절성 경화증 복합 환자의 발작 | Dravet Syndrome 참가자의 발작 | 레녹스-가스토 증후군 참가자의 발작미국
-
Cure CMD모병Emery-Dreifuss 근이영양증 | 선천성 근무력증 증후군 | 림거들 근이영양증 | ITGA7(인테그린 알파-7) 결핍을 동반한 선천성 근이영양증 | 알파-디스트로글리칸병증(심각한 간질을 동반한 디스트로글리칸의 선천성 근이영양증 및 비정상적인 글리코실화) | 알파-디스트로글리칸병증(TRAPPC11 돌연변이로 인한 지방간 및 영아 발병 백내장을 동반한 선천성 근이영양증) | 알파-디스트로글리칸병증(디스트로글리칸의 저당화를 동반한 선천성 근이영양증) | 알파-디스트로글리칸병증(디스트로글리칸 및 간질의 저당화를 동반한 선천성 근이영양증) | 알파-디스트로글리칸병증(디스트로글리칸병증... 그리고 다른 조건미국